This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Lg Life Sciences, Limited, Trioar, Inc.. Active years: 2016-2026.
Company Filing History:
Years Active: 2016-2026
Title: Ok Ku Park: Innovator in Diabetes Treatment
Introduction
Ok Ku Park is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that can aid in the treatment of diabetes and related conditions. His innovative work has led to the filing of a patent that showcases his expertise and dedication to improving health outcomes.
Latest Patents
Ok Ku Park holds a patent for "Thioaryl derivatives as GPR120 agonists." This invention relates to thioaryl derivatives of Formula 1, which are designed to promote GLP-1 formation in the gastrointestinal tract. The pharmaceutical composition derived from this invention has shown potential in improving insulin resistance in macrophages and pancreatic cells due to its anti-inflammatory properties. This innovation can be effectively utilized for preventing or treating diabetes, its complications, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis, and osteoporosis. He has 1 patent to his name.
Career Highlights
Throughout his career, Ok Ku Park has worked with prominent companies in the pharmaceutical industry. He has been associated with LG Life Sciences and LG Chem, where he has contributed to various research and development projects. His work in these organizations has allowed him to collaborate with other talented professionals in the field.
Collaborations
Some of his notable coworkers include Young Kwan Kim and Myoung Yeol Kim, who have also played significant roles in advancing research in their respective areas. Their collaborative efforts have contributed to the success of various projects and innovations.
Conclusion
Ok Ku Park is a distinguished inventor whose work in developing thioaryl derivatives has the potential to transform diabetes treatment. His contributions to the pharmaceutical industry reflect his commitment to innovation and improving health outcomes for patients.